ArticleThe American journal of pathology2013

The PPARγ agonist efatutazone increases the spectrum of well-differentiated mammary cancer subtypes initiated by loss of full-length BRCA1 in association with TP53 haploinsufficiency.

Rebecca E Nakles et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.